

GENOMICS|DIAGNOSTIC TESTS | GENETICS|R&D

Genomic Vision Signs a Strategic Partnership with the *Imagine* Institute, Europe's Largest Genetic Research and Care Cluster

- Installation of FiberVision® molecular combing platform at Necker-Enfants malades Hospital
- Development of new genetic tests to enrich Genomic Vision's portfolio in new indications

Bagneux, France (December 3, 2015) – Genomic Vision (GV: EN Paris) a French molecular diagnostics company specializing in the development of diagnostic tests for genetic diseases and cancers based on molecular combing technology, today announces the signing of a strategic partnership with the University-Hospital Institute (IHU) *Imagine*, the largest European genetic research and care cluster. The FiberVision® molecular combing platform has been installed by the Genomic Vision team at the Institute's campus of the Necker-Enfants Malades Hospital, which cares for 40,000 patients each year, more than half of which have genetic diseases.

This public-private partnership fits with Genomic Vision's strategy for the university hospital market: to form strategic collaborations with Centers of Excellence in genetic diseases and oncogenetics in order to make its innovative technology widely available in medical and academic settings.

The purpose of this collaboration with the IHU *Imagine* is to identify pathologies caused by complex structural variations that are difficult to identify with existing methods, thus contributing to the creation of new genetic tests that benefit patients and will enrich the Genomic Vision's product portfolio.

"In order to cure a genetic disease, it is first necessary to identify the genes responsible, characterize their mutations and understand the disruptions they generate. This is particularly difficult in the case of large rearrangements within the genome, which are almost undetectable with conventional technologies. Genomic Vision's molecular combing will considerably reinforce our ability to explore those mutations that give rise to numerous pathologies, in order to treat them better," **comments Professor Arnold Munnich, M.D., Founder and Director of the Department of Genetics at Necker-Enfants malades Hospital.**

Aaron Bensimon, Ph.D., Co-Founder and Chairman of the Board of Genomic Vision, concludes: *"The installation of our FiberVision® molecular combing platform in the heart of the largest European genetic research and care cluster is an important advancement for Genomic Vision. This partnership allows us to share our technological know-how in molecular diagnostics with the researchers at the Imagine Institute and create synergies for developing new diagnostic tests that will benefit many patients. The tests arising from this collaboration may create important growth engines for Genomic Vision in new indications with strong potential, while complementing our ongoing developments."*

Upcoming financial publication

- Annual Revenue for 2015, Monday, January 18, 2016* (after trading)

* indicative date, which may be subject to change

ABOUT GENOMIC VISION

Founded in 2004, Genomic Vision is a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that initially target breast and colon cancers. Since 2013, the Company has marketed the CombHelix FSHD test for identifying facioscapulohumeral dystrophy (FSHD), a myopathy that is difficult to detect. It is marketed in the United States through a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France directly by the Company. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

ABOUT MOLECULAR COMBING

DNA molecular combing technology significantly improves the structural and functional analysis of DNA molecules. DNA fibers are stretched over glass slides, as if "combed", and uniformly aligned over the entire surface. It is then possible to identify genetic anomalies by locating specific genes or sequences in the patient's genome using genetic markers, a technique developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to: www.genomicvision.com



ABOUT THE *IMAGINE* INSTITUTE

The mission of the *Imagine* Institute, the leading European cluster in genetic disease research, care and teaching, is to understand and cure these diseases. Approved as a University-Hospital Institute in 2011, *Imagine* was founded by AP-HP, Paris Descartes University, Inserm, the Hospitals of Paris-Hospitals of France Foundation, Paris City Hall and AFM-Telethon.

The Institute gathers 850 of the best doctors, researchers and health care staff in a synergy-creating architecture. It is this unprecedented continuum of expertise, associated with the proximity of patients, that allows *Imagine* to accelerate discoveries and their applications to benefit patients. www.institutimagine.org

About AP-HP:

AP-HP is an internationally recognized hospital center of European dimension. Its 39 hospitals receive 7 million patients each year: in consultations, the emergency department, scheduled hospitalizations and home visits.

It ensures a public health service for everyone, 24/7, both as a duty and source of pride. AP-HP is the largest employer of Ile-de-France: 95,000 individuals – doctors, researchers, paramedics, administrative staff and laborers – work there. www.aphp.fr

About Inserm:

Created in 1964, the French Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale, Inserm) is a public scientific and technical institution, jointly managed by the French Ministry of Higher Education and Research and the French Ministry of Health. Its researchers are dedicated to the study of all diseases, from the most common to the rarest, through their work in biological, medical and community health research. Inserm celebrated its 50th anniversary in 2014. www.inserm.fr

About the Paris Descartes University:

Paris Descartes University, the university of health and human sciences of Paris. With its nine Training and Research Units (UFR) and its Institute of Technology (IUT), the Paris Descartes University covers the entire range of human and health sciences. Its health cluster, the only university in Ile-de-France that includes medicine, pharmacy, dentistry and midwifery, is internationally recognized for the quality of its training and the excellence of its research.

CONTACTS

Genomic Vision

Aaron Bensimon
Co-Founder, Chairman of the Board of Directors
Tel.: +33 (0)1 49 08 07 50
investisseurs@genomicvision.com

Imagine Institute

Béatrice Parinello-Froment
beatriceparinello@bpfconseil.com
Tel.: +33 (0)6 63 72 16 06

Pauline Rodrigue-Moriconi
pauline.rodrigue@institutimagine.org
Tel.: +33 (0)6 77 23 71 19

NewCap

Investor Relations &
Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 (0)1 44 71 94 92
gv@newcap.eu

LHA

Investor Relations US
Anne Marie Fields, SVP
Tel.: 212-838-3777
afields@lhai.com



Member of the **CAC® Mid & Small**, **CAC® All-Tradable** and **EnterNext® PEA-PME 150** indexes

WARNING

This news release contains forward-looking statements concerning Genomic Vision and its activities. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, no guarantee can be given concerning the achievement of the expectations expressed in these forward-looking statements, which are subject to risks, including those described in the prospectus approved by the AMF under number 14-087, dated 19 March 2014, and to developments in the economic environment, financial markets and the markets in which Genomic Vision is present. The forward-looking statements that appear in this press release are also subject to risks unknown to Genomic Vision or that Genomic Vision does not consider to be significant at this time. The occurrence of any or all of these risks could lead to a significant difference between the actual results, financial conditions, performances or achievements of Genomic Vision and the results, financial conditions, performances or achievements expressed in these forward-looking statements.

This press release and the information it contains do not constitute, and cannot be interpreted as an offer or invitation for sale or subscription, or as a solicitation of any order or offer to buy or subscribe Genomic Vision shares in any country. The distribution of this press release in certain countries may constitute a breach of applicable law. Persons who come into possession of this press release should inform themselves of and observe any restrictions.

